United Therapeutics Corporation

UTHR

US91307C1027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 05/07/2024 BST			5-day change	1st Jan Change
314.6 ^USD	+1.13%		-1.25%	+43.05%

07-01	United Therapeutics Corporation(NasdaqGS:UTHR) added to Russell 1000 Defensive Index	CI
07-01	United Therapeutics Corporation(NasdaqGS:UTHR) added to Russell 1000 Value-Defensive Index	CI

United Therapeutics Corporation(NasdaqGS:UTHR) added to Russell 1000 Defensive Index

July 30, 2024

Latest news about United Therapeutics Corporation

United Therapeutics Corporation(NasdaqGS:UTHR) added to Russell 1000 Defensive Index	06-30	CI
United Therapeutics Corporation(NasdaqGS:UTHR) added to Russell 1000 Value-Defensive Index	06-30	CI
United Therapeutics Insider Sold Shares Worth $2,395,035, According to a Recent SEC Filing	06-28	MT
United Therapeutics Insider Sold Shares Worth $2,285,941, According to a Recent SEC Filing	06-28	MT
United Therapeutics Corporation Announces Board Changes	06-27	CI
Tempus, United Therapeutics Launch Collaboration to Use AI to Detect Risk of Pulmonary Hypertension	06-25	MT
Tempus AI, Inc. Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension	06-25	CI
United Therapeutics Insider Sold Shares Worth $1,033,984, According to a Recent SEC Filing	06-17	MT
United Therapeutics Insider Sold Shares Worth $1,027,716, According to a Recent SEC Filing	06-14	MT
Transcript : United Therapeutics Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 04:00 PM	06-12
Wells Fargo Raises Price Target on United Therapeutics to $350 From $325, Maintains Overweight Rating	06-12	MT
Liquidia's Yutrepia Launch Cleared as Court Denies Injunction	06-03	MT
United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing	05-16	MT
United Therapeutics Insider Sold Shares Worth $1,911,532, According to a Recent SEC Filing	05-14	MT
United Therapeutics Insider Sold Shares Worth $1,898,393, According to a Recent SEC Filing	05-10	MT
United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing	05-08	MT
United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing	05-07	MT
United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing	05-06	MT
United Therapeutics Insider Sold Shares Worth $582,195, According to a Recent SEC Filing	05-06	MT
United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing	05-03	MT
UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating	05-02	MT
Oppenheimer Adjusts United Therapeutics Price Target to $400 From $375, Maintains Outperform Rating	05-02	MT
Transcript : United Therapeutics Corporation, Q1 2024 Earnings Call, May 01, 2024	05-01
United Therapeutics Q1 Net Income, Revenue Advance; Shares Rise Pre-Bell	05-01	MT
Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Reports Q1 Revenue $677.7M, vs. Street Est of $624.2M	05-01	MT

Chart United Therapeutics Corporation

Duration

Period

More charts

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.

Sector

Biotechnology & Medical Research

Calendar

30/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for United Therapeutics Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

314.6 USD

Average target price

302.1 USD

Spread / Average Target

-3.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-15.54%	10.28B

Other Biotechnology & Medical Research